查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1575508

Esomeprazole市场：按产品类型、应用、最终用户、分销管道、年龄组划分 - 全球预测 2025-2030

Esomeprazole Market by Product Type (Dosage Strength, Over The Counter, Prescription-Based), Application (Gastroesophageal Reflux Disease, Peptic Ulcer, Zollinger-Ellison Syndrome), End User, Distribution Channel, Age Group - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年Esomeprazole市值为17.3亿美元，预计2024年将达到18.3亿美元，复合年增长率为5.92%，到2030年将达到25.9亿美元。

Esomeprazole是质子帮浦阻断剂，主要用于治疗胃食道逆流（GERD）、柔林格症候群和其他与胃酸相关的疾病。 360iResearch的市场研究分析师表示，KEYWORD的需求在于其透过减少胃酸来缓解症状和修復食道损伤的功效。其应用范围涵盖医院、诊所和家庭护理机构，最终用途尤其适用于需要长期管理酸相关病症的患者。影响埃索Esomeprazole市场的关键成长要素包括由于饮食和生活方式的改变而导致的胃食道逆流患者病率上升、认识和诊断率的提高以及全球医疗基础设施的持续扩张。此外，非处方药的趋势正在增加可近性并促进市场成长。医疗保健支出不断增加的新兴市场存在潜在机会，例如胃肠道疾病盛行率不断增加的亚太地区。製剂技术和给药系统的创新，例如延迟释放製剂和复合製剂，代表了改善生物有效性和患者依从性的有前途的研究和开发途径。然而，市场成长面临严格监管、潜在副作用以及来自学名药和替代疗法的激烈竞争等挑战。此外，发展中地区的价格敏感度和专利到期也是主要威胁。鼓励希望利用这些机会的公司优先考虑药物安全研究、有效的联合治疗和非传统市场的开拓。您还可以透过专注于病患教育工作来提高您的市场占有率。创新重点包括开发个人化医疗方法和探索新型药物输送系统以改善治疗结果。目前，Esomeprazole市场受到需求和技术进步的推动，竞争环境良好，机会充足，业务成长前景广阔。透过利用这些见解，公司可以调整其策略以克服现有挑战并优化其成长潜力。

主要市场统计
基准年[2023] 17.3亿美元
预测年份 [2024] 18.3亿美元
预测年份 [2030] 25.9亿美元
复合年增长率（%） 5.92%

市场动态：揭示快速发展的Esomeprazole市场的关键市场洞察

供需的动态交互作用正在改变Esomeprazole市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 全球胃肠道疾病盛行率上升
    • 扩大医疗基础设施以改善胃肠道治疗的可近性
    • 支持Esomeprazole在医疗环境中使用的有利政府政策和报销制度
  • 市场限制因素
    • 与Esomeprazole相关的监管和合规问题
  • 市场机会
    • 製药公司之间的策略合作和伙伴关係，以创新基于Esomeprazole的治疗方法
    • 持续的研发工作导致先进的Esomeprazole製剂的推出
  • 市场挑战
    • Esomeprazole生产原料缺乏

波特的五力：驾驭Esomeprazole市场的策略工具

波特的五力架构是了解Esomeprazole市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解Esomeprazole市场的外部影响

外部宏观环境因素在塑造Esomeprazole市场表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解Esomeprazole市场的竞争状况

对Esomeprazole市场的详细市场占有率分析可以对供应商的业绩进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵Esomeprazole市场供应商的绩效评估

FPNV定位矩阵是评估Esomeprazole市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了Esomeprazole市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，Esomeprazole市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球胃肠道疾病的发生率正在上升
      • 扩大医疗基础设施改善胃肠道治疗的可近性
      • 有利的政府政策和报销制度支持Esomeprazole在医疗机构中的使用
    • 抑制因素
      • 与Esomeprazole相关的监管和合规问题
    • 机会
      • 製药公司之间的策略合作和伙伴关係，以创新Esomeprazole为基础的治疗方法
      • 不断的研究和开发努力推出了先进的Esomeprazole
    • 任务
      • Esomeprazole生产原料缺乏
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章Esomeprazole市场：依产品类型

  • 剂量强度
    • 高剂量
    • 低剂量
    • 中等剂量
  • 店面销售(OTC)
    • 胶囊
    • 其他格式
    • 暂停
    • 药片
  • 根据处方笺
    • 胶囊
    • 注射
    • 暂停
    • 药片

第七章Esomeprazole市场：依应用分类

  • 胃食道逆流症（GERD）
    • 急性治疗
    • 维持治疗
  • 消化性溃疡
    • 十二指肠溃疡
    • 胃溃疡
  • 柔林格症候群

第 8 章Esomeprazole市场：依最终用户分类

  • 诊所
    • 普通科诊所
    • 专科诊所
  • 家庭护理设置
  • 医院
    • 私立医院
    • 公立医院

第九章Esomeprazole市场：按分销管道

  • 药局
  • 医院药房
  • 网路药房
  • 零售药房

第10章Esomeprazole市场：依年龄组

  • 成人用
  • 老年病
  • 小儿科

第十一章美洲Esomeprazole市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十二章亚太地区Esomeprazole市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十三章 欧洲、中东和非洲Esomeprazole市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第14章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-535C6291879C

The Esomeprazole Market was valued at USD 1.73 billion in 2023, expected to reach USD 1.83 billion in 2024, and is projected to grow at a CAGR of 5.92%, to USD 2.59 billion by 2030.

Esomeprazole, a proton pump inhibitor, is primarily used to treat gastroesophageal reflux disease (GERD), Zollinger-Ellison syndrome, and other acid-related disorders. As the market research analyst at 360iResearch, the necessity of esomeprazole lies in its effectiveness in reducing stomach acid, thereby providing symptom relief and healing esophageal damage. Its application spans across hospitals, clinics, and homecare settings, with end-use notably being patients requiring long-term management of acid-related conditions. Key growth factors influencing the esomeprazole market include the rising prevalence of GERD due to dietary and lifestyle changes, increasing awareness and diagnosis rates, and the ongoing expansion of healthcare infrastructure globally. Furthermore, the trend towards over-the-counter availability facilitates easier access, propelling market growth. Potential opportunities reside in emerging markets with increasing healthcare expenditure like Asia-Pacific, where the prevalence of gastrointestinal disorders is rising. Innovations in formulation technology and delivery systems present a promising avenue for R&D, offering enhanced bioavailability and patient compliance, such as delayed-release or co-formulation products. On the other hand, market growth faces challenges from stringent regulations, potential side effects, and the intense competition from generics and alternative therapies. Additionally, price sensitivity in developing regions and patent expirations pose significant threats. For businesses aiming to capitalize on these opportunities, prioritizing research in drug safety, effective combination therapies, and exploring non-traditional markets are recommended. Emphasizing patient education initiatives can also enhance market presence. Innovation focuses could include the development of personalized medicine approaches and exploring novel drug delivery systems for improved therapeutic outcomes. The esomeprazole market currently exhibits a competitive yet opportunity-rich environment, driven by both necessity and technological advancement, offering robust prospects for business growth. By leveraging these insights, companies can align strategies to navigate existing challenges and optimize growth potential.

KEY MARKET STATISTICS
Base Year [2023] USD 1.73 billion
Estimated Year [2024] USD 1.83 billion
Forecast Year [2030] USD 2.59 billion
CAGR (%) 5.92%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Esomeprazole Market

The Esomeprazole Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of gastrointestinal disorders globally
    • Expanding healthcare infrastructure improving access to gastrointestinal therapies
    • Favorable government policies and reimbursement schemes supporting the use of esomeprazole in medical practice
  • Market Restraints
    • Regulatory and compliance issues associated with esomeprazole
  • Market Opportunities
    • Strategic collaborations and partnerships among pharmaceutical companies to innovate esomeprazole-based treatments
    • Ongoing research and development efforts leading to the introduction of advanced esomeprazole formulations
  • Market Challenges
    • Raw material shortages for the production of esomeprazole

Porter's Five Forces: A Strategic Tool for Navigating the Esomeprazole Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Esomeprazole Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Esomeprazole Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Esomeprazole Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Esomeprazole Market

A detailed market share analysis in the Esomeprazole Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Esomeprazole Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Esomeprazole Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Esomeprazole Market

A strategic analysis of the Esomeprazole Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Esomeprazole Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Amneal Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Cipla, Dr. Reddy's Laboratories, Eli Lilly and Company, Glenmark Pharmaceuticals, Lupin Pharmaceuticals, Merck & Co., Mylan, Novartis, Pfizer, Sandoz, Sanofi, Sun Pharmaceutical, Takeda Pharmaceutical Company, Teva Pharmaceuticals, Torrent Pharmaceuticals, and Zydus Cadila.

Market Segmentation & Coverage

This research report categorizes the Esomeprazole Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product Type, market is studied across Dosage Strength, Over The Counter (OTC), and Prescription-Based. The Dosage Strength is further studied across High Dosage, Low Dosage, and Medium Dosage. The Over The Counter (OTC) is further studied across Capsules, Other Forms, Suspensions, and Tablets. The Prescription-Based is further studied across Capsules, Injection, Suspensions, and Tablets.
  • Based on Application, market is studied across Gastroesophageal Reflux Disease (GERD), Peptic Ulcer, and Zollinger-Ellison Syndrome. The Gastroesophageal Reflux Disease (GERD) is further studied across Acute Treatment and Maintenance Treatment. The Peptic Ulcer is further studied across Duodenal Ulcer and Gastric Ulcer.
  • Based on End User, market is studied across Clinics, Homecare Settings, and Hospitals. The Clinics is further studied across General Clinics and Specialty Clinics. The Hospitals is further studied across Private Hospitals and Public Hospitals.
  • Based on Distribution Channel, market is studied across Drug Stores, Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
  • Based on Age Group, market is studied across Adult, Geriatric, and Pediatric.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of gastrointestinal disorders globally
      • 5.1.1.2. Expanding healthcare infrastructure improving access to gastrointestinal therapies
      • 5.1.1.3. Favorable government policies and reimbursement schemes supporting the use of esomeprazole in medical practice
    • 5.1.2. Restraints
      • 5.1.2.1. Regulatory and compliance issues associated with esomeprazole
    • 5.1.3. Opportunities
      • 5.1.3.1. Strategic collaborations and partnerships among pharmaceutical companies to innovate esomeprazole-based treatments
      • 5.1.3.2. Ongoing research and development efforts leading to the introduction of advanced esomeprazole formulations
    • 5.1.4. Challenges
      • 5.1.4.1. Raw material shortages for the production of esomeprazole
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Esomeprazole Market, by Product Type

  • 6.1. Introduction
  • 6.2. Dosage Strength
    • 6.2.1. High Dosage
    • 6.2.2. Low Dosage
    • 6.2.3. Medium Dosage
  • 6.3. Over The Counter (OTC)
    • 6.3.1. Capsules
    • 6.3.2. Other Forms
    • 6.3.3. Suspensions
    • 6.3.4. Tablets
  • 6.4. Prescription-Based
    • 6.4.1. Capsules
    • 6.4.2. Injection
    • 6.4.3. Suspensions
    • 6.4.4. Tablets

7. Esomeprazole Market, by Application

  • 7.1. Introduction
  • 7.2. Gastroesophageal Reflux Disease (GERD)
    • 7.2.1. Acute Treatment
    • 7.2.2. Maintenance Treatment
  • 7.3. Peptic Ulcer
    • 7.3.1. Duodenal Ulcer
    • 7.3.2. Gastric Ulcer
  • 7.4. Zollinger-Ellison Syndrome

8. Esomeprazole Market, by End User

  • 8.1. Introduction
  • 8.2. Clinics
    • 8.2.1. General Clinics
    • 8.2.2. Specialty Clinics
  • 8.3. Homecare Settings
  • 8.4. Hospitals
    • 8.4.1. Private Hospitals
    • 8.4.2. Public Hospitals

9. Esomeprazole Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Drug Stores
  • 9.3. Hospital Pharmacies
  • 9.4. Online Pharmacies
  • 9.5. Retail Pharmacies

10. Esomeprazole Market, by Age Group

  • 10.1. Introduction
  • 10.2. Adult
  • 10.3. Geriatric
  • 10.4. Pediatric

11. Americas Esomeprazole Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Esomeprazole Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Esomeprazole Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Amneal Pharmaceuticals
  • 3. AstraZeneca
  • 4. Boehringer Ingelheim
  • 5. Cipla
  • 6. Dr. Reddy's Laboratories
  • 7. Eli Lilly and Company
  • 8. Glenmark Pharmaceuticals
  • 9. Lupin Pharmaceuticals
  • 10. Merck & Co.
  • 11. Mylan
  • 12. Novartis
  • 13. Pfizer
  • 14. Sandoz
  • 15. Sanofi
  • 16. Sun Pharmaceutical
  • 17. Takeda Pharmaceutical Company
  • 18. Teva Pharmaceuticals
  • 19. Torrent Pharmaceuticals
  • 20. Zydus Cadila

LIST OF FIGURES

  • FIGURE 1. ESOMEPRAZOLE MARKET RESEARCH PROCESS
  • FIGURE 2. ESOMEPRAZOLE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL ESOMEPRAZOLE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. ESOMEPRAZOLE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. ESOMEPRAZOLE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. ESOMEPRAZOLE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL ESOMEPRAZOLE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. ESOMEPRAZOLE MARKET DYNAMICS
  • TABLE 7. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY HIGH DOSAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY LOW DOSAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY MEDIUM DOSAGE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY OTHER FORMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY INJECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY ACUTE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY MAINTENANCE TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY DUODENAL ULCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY GASTRIC ULCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY ZOLLINGER-ELLISON SYNDROME, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY GENERAL CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY HOMECARE SETTINGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL ESOMEPRAZOLE MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 56. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 67. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. CANADA ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 93. CANADA ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 94. CANADA ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 97. CANADA ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 103. MEXICO ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. MEXICO ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 105. MEXICO ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 115. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 117. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES ESOMEPRAZOLE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 153. CHINA ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. CHINA ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 155. CHINA ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 156. CHINA ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 159. CHINA ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 165. INDIA ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. INDIA ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 167. INDIA ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 168. INDIA ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 171. INDIA ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 177. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 179. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 189. JAPAN ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. JAPAN ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 191. JAPAN ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 201. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 203. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. MALAYSIA ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 213. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 215. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. PHILIPPINES ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 225. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 227. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 234. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 235. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. SINGAPORE ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 237. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH KOREA ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 249. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 251. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 258. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 259. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 260. TAIWAN ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 261. THAILAND ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. THAILAND ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 263. THAILAND ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 270. THAILAND ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 271. THAILAND ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. THAILAND ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 273. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 275. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 280. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 282. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 283. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. VIETNAM ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA ESOMEPRAZOLE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 298. DENMARK ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 299. DENMARK ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 300. DENMARK ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 301. DENMARK ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 302. DENMARK ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 303. DENMARK ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 304. DENMARK ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 305. DENMARK ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 306. DENMARK ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 307. DENMARK ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 308. DENMARK ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 309. DENMARK ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 310. EGYPT ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 311. EGYPT ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 312. EGYPT ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 313. EGYPT ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 314. EGYPT ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 315. EGYPT ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 316. EGYPT ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 317. EGYPT ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 318. EGYPT ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 319. EGYPT ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 320. EGYPT ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 321. EGYPT ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 322. FINLAND ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 323. FINLAND ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 324. FINLAND ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 325. FINLAND ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 326. FINLAND ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 327. FINLAND ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 328. FINLAND ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 329. FINLAND ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 330. FINLAND ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 331. FINLAND ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 332. FINLAND ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 333. FINLAND ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 334. FRANCE ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 335. FRANCE ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 336. FRANCE ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 337. FRANCE ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 338. FRANCE ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 339. FRANCE ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 340. FRANCE ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 341. FRANCE ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 342. FRANCE ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 343. FRANCE ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 344. FRANCE ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 345. FRANCE ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 346. GERMANY ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 347. GERMANY ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 348. GERMANY ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 349. GERMANY ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 350. GERMANY ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 351. GERMANY ESOMEPRAZOLE MARKET SIZE, BY GASTROESOPHAGEAL REFLUX DISEASE (GERD), 2018-2030 (USD MILLION)
  • TABLE 352. GERMANY ESOMEPRAZOLE MARKET SIZE, BY PEPTIC ULCER, 2018-2030 (USD MILLION)
  • TABLE 353. GERMANY ESOMEPRAZOLE MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 354. GERMANY ESOMEPRAZOLE MARKET SIZE, BY CLINICS, 2018-2030 (USD MILLION)
  • TABLE 355. GERMANY ESOMEPRAZOLE MARKET SIZE, BY HOSPITALS, 2018-2030 (USD MILLION)
  • TABLE 356. GERMANY ESOMEPRAZOLE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 357. GERMANY ESOMEPRAZOLE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 358. ISRAEL ESOMEPRAZOLE MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 359. ISRAEL ESOMEPRAZOLE MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 360. ISRAEL ESOMEPRAZOLE MARKET SIZE, BY OVER THE COUNTER (OTC), 2018-2030 (USD MILLION)
  • TABLE 361. ISRAEL ESOMEPRAZOLE MARKET SIZE, BY PRESCRIPTION-BASED, 2018-2030 (USD MILLION)
  • TABLE 362. ISRAEL ESOMEPRAZOLE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 363. ISRAEL ESOMEPRAZOLE MA